{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:23:22Z","timestamp":1783646602926,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T00:00:00Z","timestamp":1153440000000},"content-version":"vor","delay-in-days":5346,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1991,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The relationship between the strength of the estrogenic and progestational components of combined oral contraceptives and risk of endometrial carcinoma was examined in a multinational hospital\u2010based case\u2010control study comparing 220 cases from 7 countries with 1,537 age\u2010 and hospital\u2010matched controls. Oral contraceptives were classified according to their relative content of estrogen and progestin. The risk was not altered in women who used preparations containing high\u2010dose estrogen\/low\u2010dose progestin compounds [odds ratio (OR) = 1.10, 95% CI = 0.13\u20109.96]. In contrast, the risk among users of low\u2010dose estrogen\/high\u2010dose progestin oral contraceptives was greatly decreased (OR = 0,95% CI = 0\u20101.08). Risks observed for users of high\u2010dose estrogen\/high\u2010dose progestin (OR = 0.15, 95% CI = 0.045\u20100.50) and low\u2010dose estrogen\/low\u2010dose progesterone (OR = 0.59,95% CI = 0.26\u20101.30) preparations were intermediate between those for users of the 2 other types of preparation. A significantly lower risk was observed for high\u2010dose progestin users than for low\u2010dose users [ratio of odds ratios (ROR) = 0.21, 95% CI = 0.05\u20100.84]. Although the numbers are small, findings from this study suggest that combined oral contraceptives with varying strengths of estrogen and progestin have different effects on the risk of endometrial carcinoma.<\/jats:p>","DOI":"10.1002\/ijc.2910490612","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T22:46:59Z","timestamp":1171925219000},"page":"870-874","source":"Crossref","is-referenced-by-count":33,"title":["Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma"],"prefix":"10.1002","volume":"49","author":[{"given":"Karin A.","family":"Rosenblatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,21]]},"reference":[{"key":"e_1_2_1_2_1","unstructured":"The WHO Collaborative Study of Neoplasia and Steroid Contraceptives"},{"key":"e_1_2_1_3_1","volume-title":"Lower\u2010dose pills. Population reports","year":"1988"},{"key":"e_1_2_1_4_1","volume-title":"Drug evaluations","author":"American Medical Association","year":"1986"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00560348"},{"key":"e_1_2_1_6_1","volume-title":"Statistical methods in cancer research. Volume 1\u2013The analysis of case\u2010control studies","author":"Breslow N. E.","year":"1980"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jama.1987.03390060086029","article-title":"Combination oral contraceptive use and the risk of endometrial cancer","volume":"257","author":"Cash","year":"1987","journal-title":"J. Amer. Med. Ass."},{"key":"e_1_2_1_8_1","volume-title":"Managing contraceptive pill patients","author":"Dickey R. P.","year":"1984"},{"key":"e_1_2_1_9_1","first-page":"106","article-title":"Progestational potency of oral contraceptives","volume":"47","author":"Dickey R. P.","year":"1976","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(85)90056-3"},{"key":"e_1_2_1_11_1","first-page":"162","article-title":"Progestational potency of oral Contraceptives: a polemic","volume":"23","author":"Edgren R. A.","year":"1978","journal-title":"Int. J. Fertil."},{"key":"e_1_2_1_12_1","volume-title":"International Encyclopedia of Pharmacology and Therapeutics","author":"Ferin J.","year":"1972"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1967.tb15578.x"},{"key":"e_1_2_1_14_1","first-page":"37","article-title":"Progestational agents in clinical practice","volume":"18","author":"Greenblatt R. B.","year":"1967","journal-title":"Med. Sci."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1983.127"},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jama.1982.03320290021022","article-title":"Protection against endometrial carcinoma by combination\u2010product oral contraceptives","volume":"247","author":"Hulka B. S.","year":"1982","journal-title":"J. Amer. med. Ass."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.2307\/2288562"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6667.147"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/16.2.215"},{"key":"e_1_2_1_20_1","volume-title":"International histologic classification of tumors","author":"Poulsen H. E.","year":"1975"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60801-5"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.1370050506"},{"key":"e_1_2_1_23_1","first-page":"118","article-title":"The estrogenic potency of ethinyl estradiol and mestranol\u2013a comparative stidy","volume":"173","author":"Schwartz U.","year":"1973","journal-title":"Acta endocr. Suppl."},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(89)90378-7"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-0867-6_1"},{"key":"e_1_2_1_26_1","first-page":"768","article-title":"The effect of progestogen use on endometrial cancer in women who use exogenous estrogen. (Abstract)","volume":"132","author":"Voigt L. F.","year":"1990","journal-title":"Amer. J. Epidemiol."},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198003063021004"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198112313052701"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/17.2.263"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/18.3.538"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490208"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910490612","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910490612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T02:39:13Z","timestamp":1698028753000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910490612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1991,12]]}},"alternative-id":["10.1002\/ijc.2910490612"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910490612","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,12]]}}}